Facebook
Twitter
LinkedIn
ForwardHead and Neck Cancer Symposium, Seventh Annual
Personalized medicine helps doctors learn about a person’s genetic makeup and how his or her tumor grows. Modern personalized medicine is based on targeted therapy. In targeted therapy, it is essential that information about the altered pathway and the components leading to cancer are available. During this symposium, physicians will discuss the treatment modalities, prognosis and clinical trials associated with head and neck cancer.
Complete details at HNCancerSymposium.BaptistHealth.net
Target Audience
Primary Care Physicians, Dentists, Otolaryngologists, Gastroenterologists, Radiologists, Medical Oncologists, Oral Maxillofacial Surgeons, Surgeons, Pathologists, Pediatricians, Hospitalists, Nurses, Occupational Therapists, Radiology Technologists and Pharmacists.
Learning Objectives
- Assess the history and physical examination of potential head and neck cancer patients.
- Explain the importance of mouth care prior to cancer therapies.
- Recommend treatment options for dental treatment prior to cancer therapy.
- Describe how radiation guards can protect oral tissues to decrease adverse effects of head and neck radiation therapy.
- Implement optimal dental care to get patients ready for head and neck radiation therapy.
- Describe the rationale to consider proton therapy for head and neck cancer patients.
- Explain which head and neck cancer patients benefit most from proton therapy.
- Determine what tumor invasion of the mandible require complete resection in order to be oncologically safe.
- Identify when to use a vascularized flap versus a non-vascularized bone graft to reconstruct the mandible.
- Determine techniques for the functional structure and aesthetic reconstruction of maxillary bone defects using computer-assisted design.
- Summarize appropriate treatment options for patients being treated for head and neck cancer.
- Discuss treatment updates and advances in trans-oral robotic surgery (TORS).
- Implement appropriate treatment options using TORS.
- Describe the role of chemotherapy and targeted curative therapies including induction and definitive and adjuvant settings for head and neck cancer.
- Summarize data leading to recent approval of immunotherapy in a palliative setting in head and neck cancer.
- Implement appropriate rehabilitative services for cancer survivors and their families.
Michael D. Chuong, M.D.
Radiation Oncologist
Baptist Health Quality Network
Baptist and South Miami Hospitals
Miami, Florida
Michael D. Chuong, M.D. has indicated that he is a consultant for QuantiaMD and his discussion will not include mention of investigational or off-label usage or unapproved product usage in his presentation(s) or discussion(s).
Adrian Cristian, M.D.
Physical Medicine and Rehabilitation
Baptist Hospital of Miami
Miami, Florida
Adrian Cristian, M.D. has indicated that he is a consultant for QuantiaMD and his discussion will not include mention of investigational or off-label usage or unapproved product usage in his presentation(s) or discussion(s).
Carol Horkowitz-Tsaoussis, DMD
Prosthodontist
Baptist Hospital of Miami
Miami, Florida
Carol Horkowitz-Tsaoussis, DMD indicated that neither she nor her spouse/partner have relevant financial relationships with commercial interest companies, and she will not include off-label or unapproved product usage in her presentation(s) or discussion(s).
Shawn A. McClure, M.D., DMD
Oral Maxillofacial Surgeon
Baptist and South Miami Hospitals
Residency Program Director
Nova/NSU Department of Oral and Maxillofacial Surgery
Shawn A. McClure, M.D., DMD, indicated that neither he nor his spouse/partner has relevant financial relationships with commercial interest companies, and he will not include off-label or unapproved product usage in his presentation(s) or discussion(s).
Miguel A. Medina, III, M.D.
Director of Microsurgery
Plastic and Reconstructive Surgery
Miami Cancer Institute
Miami, Florida
Miguel A. Medina, III, M.D., indicated that neither he nor his spouse/partner has relevant financial relationships with commercial interest companies, and he will not include off-label or unapproved product usage in his presentation(s) or discussion(s).
Jose Montero, DDS
Miami Oral & Maxillofacial Surgery
Miami, Florida
Jose Montero, DDS, indicated that neither he nor his spouse/partner has relevant financial relationships with commercial interest companies, and he will not include off-label or unapproved product usage in his presentation(s) or discussion(s).
Francisco G. Pernas, M.D.
Otolaryngologist
South Florida ENT Associates
Miami, Florida
Francisco G. Pernas, M.D., indicated that neither he nor his spouse/partner has relevant financial relationships with commercial interest companies, and he will not include off-label or unapproved product usage in his presentation(s) or discussion(s).
Guilherme Rabinowits, M.D.
Head and Neck and Cutaneous Medical Oncology
Co-Leader, Head and Neck Disease Management Team
Miami Cancer Institute
Miami, Florida
Guilherme Rabinowits, M.D. has indicated that he is a consultant for Pfizer, EMD Serono, he is a stock shareholder with Syroes Pharmaceuticals and Regeneron and has received grant/research support from EMD Serono, Exelixis and Millenium and his discussion will not include mention of investigational or off-label usage or unapproved product usage in his presentation(s) or discussion(s).
Geoffrey D. Young, M.D. Ph.D., FACS
Chief – Head and Neck Surgery
Miami Cancer Institute
Miami, Florida
Geoffrey D. Young, M.D indicated that neither he nor his spouse/partner has relevant financial relationships with commercial interest companies, and he will not include off-label or unapproved product usage in his presentation(s) or discussion(s).
Joseph P. McCain, DMD, FACS
SYMPOSIUM DIRECTOR
Oral and Maxillofacial Surgeon
Subsection Chief of OMS
Baptist Hospital of Miami
Chief of OMS
Florida International University
Herbert Wertheim School of Medicine
Miami, Florida
Andre A. Abitbol, M.D.
Planning Committee
Radiation Oncologist
Department of Radiation Oncologist
Miami Cancer Institute
Michael B. Troner, M.D.
Planning Committee
Hematology/Oncology
Baptist, Doctors, and
West Kendall Baptist Hospitals
Baptist Health South Florida is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Baptist Health has been re-surveyed by the ACCME and awarded Commendation for 6 years as a provider of CME for physicians.
Baptist Health South Florida designates this live activity for a maximum of 3.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been approved for 3.25 credit hours by the Florida Boards of Medicine, Osteopathic Medicine and the Florida Council of Physician Assistants. CE Broker #20-616109.
The American Academy of Nurse Practitioners Certification Board (AANPCB) accepts CEs accredited by the ACCME. Individuals are responsible for checking with the AANPCB for further guidelines.
.
Available Credit
- 3.25 AMA PRA Category 1 Credit™
- 3.25 General certificate of attendance
- 3.00 Florida Board of Dentistry
- 3.00 Nurse Practitioners
- 3.00 Florida Board of Nursing
- 3.00 Florida Board of Occupational Therapy
- 3.25 Florida Board of Pharmacy
- 3.25 Florida Bureau of Radiation Control
Required Hardware/Software
Technical Support: If you are experiencing technical difficulties or have received an error message, please send an email to CME@BaptistHealth.net and include a print screen of the error message, your browser name and version, username and URL where the error occurred. You can expect a response within 48 hours.